These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3180904)

  • 1. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
    Badian M; Malerczyk V; Collins JD; Dixon GT; Verho M; Eckert HG
    Chemotherapy; 1988; 34(5):367-73. PubMed ID: 3180904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.
    Malerczyk V; Maass L; Verho M; Hajdú P; Klesel N; Rangoonwala R
    Infection; 1987; 15(3):211-4. PubMed ID: 3610330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.
    Maass L; Malerczyk V; Verho M; Hajdú P; Seeger K; Klesel N
    Infection; 1987; 15(3):202-6. PubMed ID: 3610328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
    Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.
    Nakayama I; Akieda Y; Yamaji E; Nitta Y; Ohishi M; Katagiri K; Imamura N; Takase K
    J Clin Pharmacol; 1992 Mar; 32(3):256-66. PubMed ID: 1564130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
    Lameire N; Malerczyk V; Drees B; Lehr K; Rosenkranz B
    Clin Pharmacol Ther; 1992 Jul; 52(1):24-30. PubMed ID: 1623690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.
    Maass L; Malerczyk V; Verho M
    Infection; 1987; 15(3):207-10. PubMed ID: 3610329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
    Lipman J; Wallis SC; Rickard CM; Fraenkel D
    Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic.
    Verho M; Maass L; Malerczyk V; Grötsch H
    Infection; 1987; 15(3):215-9. PubMed ID: 2886437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the pharmacokinetics of cefpirome sulphate in the elderly.
    Sugihara H; Narita N; Takatsu R; Horiuchi M; Yonenami K; Hotta M; Shibahara K; Kamo T; Negishi Y
    J Clin Pharm Ther; 1998 Oct; 23(5):375-9. PubMed ID: 9875686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
    Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
    Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.
    Isert D; Klesel N; Limbert M; Markus A; Seibert G; Schrinner E
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():31-7. PubMed ID: 1601754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria.
    Roos JF; Lipman J; Kirkpatrick CMJ
    Intensive Care Med; 2007 May; 33(5):781-788. PubMed ID: 17342515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of cefpirome--rationale for a twelve-hour dosing regimen.
    Craig WA
    Scand J Infect Dis Suppl; 1993; 91():33-40. PubMed ID: 8290901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.
    Hollenstein U; Brunner M; Mayer BX; Delacher S; Erovic B; Eichler HG; Müller M
    Clin Pharmacol Ther; 2000 Mar; 67(3):229-36. PubMed ID: 10741625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
    Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
    Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefpirome clinical pharmacokinetics.
    Strenkoski LC; Nix DE
    Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.